Related Experiment Video
Updated: Oct 12, 2025
Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis
Published on: January 21, 2020
Comparison between biodegradable- and durable-polymer everolimus-eluting stents in hemodialysis patients with
Ryuta Ito1, Hideki Ishii2, Satoru Oshima3
1Department of Cardiology, Nagoya Kyoritsu Hospital, 1-172 Hokke, Nakagawa-ku, Nagoya, Aichi, 454-0933, Japan. r-ito@kaikou.or.jp.
Insights
Biodegradable-polymer (BP) and durable-polymer (DP) everolimus-eluting stents (EES) showed similar clinical outcomes in hemodialysis patients with coronary artery disease over two years. Target lesion revascularization and major adverse cardiac events were comparable between BP-EES and DP-EES groups.
Area of Science:
- Cardiology
- Biomaterials Science
Background:
- Coronary artery disease (CAD) is a significant concern for hemodialysis (HD) patients.
- Everolimus-eluting stents (EES) are used to treat CAD, with variations in polymer coatings.
- Biodegradable-polymer (BP) EES and durable-polymer (DP) EES differ in their material composition and drug elution profiles.
Purpose of the Study:
- To compare the 2-year clinical outcomes of BP-EES versus DP-EES implantation in HD patients with CAD.
- To evaluate the incidence of target lesion revascularization (TLR) and major adverse cardiac events (MACE) between the two stent types.
- To assess restenosis rates via follow-up coronary angiography.
Main Methods:
- A cohort of 221 consecutive HD patients treated with EES for coronary lesions was retrospectively analyzed.
- Patients were divided into BP-EES (n=91) and DP-EES (n=130) groups.
- Propensity-score matching was performed, and clinical outcomes (TLR, MACE, mortality, myocardial infarction) and angiographic restenosis were assessed over 2 years.
Main Results:
- Baseline characteristics showed lower rates of male sex and diabetes in the BP-EES group.
- The use of debulking devices was significantly lower in the BP-EES group.
- At 2 years, TLR and MACE rates were comparable between the BP-EES and DP-EES groups, both in the overall and propensity-score matched cohorts (TLR: 19.2% vs. 20.4%, p=0.73; MACE: 26.9% vs. 34.2%, p=0.93).
- Restenosis rates were also similar between the groups (p=0.79).
Conclusions:
- Biodegradable-polymer everolimus-eluting stents and durable-polymer everolimus-eluting stents demonstrate similar 2-year clinical efficacy and safety in hemodialysis patients with coronary artery disease.
- The choice between BP-EES and DP-EES does not appear to significantly impact major adverse cardiac events or target lesion revascularization in this high-risk population.
- Further research may explore long-term outcomes and specific patient subgroups.
Abstract:
To investigate the clinical outcomes after biodegradable-polymer (BP) and durable-polymer (DP) everolimus-eluting stent (EES) implantation in hemodialysis (HD) patients with coronary artery disease. We enrolled 221 consecutive HD patients successfully treated with EES implantation for coronary lesions. Over the following 2 years, we assessed the incidence of target lesion revascularization (TLR) and major adverse cardiac event (MACE), defined as the composite endpoint of TLR, all-cause mortality, or myocardial infarction. We performed a propensity-score matching analysis and collected follow-up coronary angiography data. There were 91 patients in the BP-EES group and 130 in the DP-EES group. Male sex and diabetes rates were significantly lower in the BP-EES group than in the DP-EES group. A debulking device was less frequently used in the BP-EES group than in the DP-EES group (7.6% vs. 21.5%, p = 0.006). TLR occurred in 38 patients, while stent thrombosis was observed in 3 patients; 19 patients died. TLR and MACE rates at 2 years were comparable between the two groups (19.2% in the BP-EES group vs. 20.4% in the DP-EES group, p = 0.73 and 26.9% vs. 34.2%, p = 0.93, respectively). In the propensity-score-matched cohort, TLR and MACE rates were similar between the two groups (19.2% in the BP-EES group vs. 18.1% in the DP-EES group, p = 0.69, and 26.9% vs. 30.2%, p = 0.66, respectively). Restenosis rates at follow-up angiography were similar between the two groups (p = 0.79). In hemodialysis patients, BP-EES and DP-EES showed similar 2-year clinical outcomes.
Related Concept Videos
01:30Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
01:24Hemodialysis II: Procedure and Complications
01:25Hemodialysis I: Introduction
01:25Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
01:26Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
01:27Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...